Letters by company

Agios Pharmaceuticals, INC.

1 letter discussing AGIO. Everything written about it on this site is on its ticker page.

ROCKLINC Investment Partners Third Quarter Report 2026 ROCKLINC argues that protected property rights, sound money, limited government and real assets are essential safeguards against policy-driven currency debasement. The firm retained its core holdings, kept meaningful cash reserves, emphasized precious-metals royalty businesses, and presents Royalty Pharma as a capital-light buyer of pharmaceutical royalty streams. Q3 2026 RPRX $39BOR $6.4B